Fast antibiotic sensitivity tests to guide treatment for bloodstream infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ACT-FAST is a multicenter, open-label, randomized adaptive platform that compares rapid antimicrobial susceptibility testing (R-AST) tools with standard laboratory workflows for patients with positive blood cultures. Participants are randomized to R-AST-guided reporting or to the site’s usual diagnostics, with treating clinicians adjusting antibiotics based on the results and clinical judgment. The adaptive design allows new R-AST technologies to be added over time and randomization ratios to be modified as evidence accumulates. Patients are followed for 28 days to compare antimicrobial stewardship metrics and clinical outcomes between strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients admitted to emergency department or hospitalized for any cause in participating hospitals with clinically suspected BSI and positive blood culture.
* At least 18 years of age.

Exclusion Criteria:

* Have previously taken part in this trial.
* Concurrently participating in the active phase of a study considered incompatible.
* Patient with severe or terminal disease with life expectancy shorter than 48 h.
* Have an existing directive to withhold life-sustaining treatment, in relation to antibiotic use.

Where it's running

• Infectious Disease Unit - IRCCS Humanitas Research Hospital
  Rozzano, Milan, Italy Recruiting

Study contacts

• Study coordinator: Michele Bartoletti, MD, PhD
• Email: michele.bartoletti@hunimed.eu
• Phone: + 39 02 8224 3568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral switch for bloodstream infections in immunocompromised children

  This trial tests whether switching from IV to oral antibiotics is just as safe as continuing IV therapy for children with bloodstream infections who are immunocompromised or have a central venous catheter.

  Recruiting at 4 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Aalborg and 3 other locations · NCT07923266

• Oral switch for kids with bloodstream infections after starting IV therapy

  This trial will test whether switching from IV to oral antibiotics early is not worse than continuing IV treatment for previously healthy children and teens with uncomplicated bloodstream infections.

  Recruiting at 18 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Aabenraa and 17 other locations · NCT07791914

• Personalized antibiotic duration for high-risk febrile neutropenia with Gram-negative bloodstream infection

  This trial tests whether stopping antibiotics after a patient with a blood cancer and febrile neutropenia has been clinically stable for 72 hours is as safe and lets them spend more days off anti–Gram-negative antibiotics than the usual at least 10-day approach.

  Recruiting Humanitas University · Rozzano, Milan · NCT07372131

• Middle East study of bloodstream infections in blood cancer patients and HSCT recipients

  This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.

  Recruiting at 9 sites Hamad Medical Corporation · Amman and 8 other locations · NCT07900542

• Sulbactam-Durlobactam for CRAB infections in real-world care

  This real-world study tests whether sulbactam-durlobactam works and is safe for adults with carbapenem-resistant Acinetobacter baumannii infections, compared with other anti-CRAB treatments.

  Recruiting Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT07601711

• Ceftazidime (±avibactam) with IV fosfomycin versus ceftazidime alone for hospitalized adults with severe suspected Gram‑negative infection

  This trial will test whether adding intravenous fosfomycin to ceftazidime (or ceftazidime‑avibactam) helps hospitalized adults with suspected severe Gram‑negative infections recover faster than ceftazidime alone.

  Recruiting Phase 3 University of Geneva, Switzerland · Geneva, Canton of Geneva · NCT07063095

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.